AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22472744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 20051897 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory group intervention focusing on internal strategy use
Number of subjects: 94
Study 20051897 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study 18773723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatic information (red/green) in motion integration; measured through psychophysical reports.
Number of subjects: 0
Study 18773723 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance information (bright/dark) in motion integration; measured through psychophysical reports.
Number of subjects: 0
Study 18773723 — intervention group
Group type: COMPARATOR
Intervention: Chromatic information (red/green) in motion integration; measured through eye-movement measures.
Number of subjects: 0
Study 18773723 — intervention group
Group type: COMPARATOR
Intervention: Luminance information (bright/dark) in motion integration; measured through eye-movement measures.
Number of subjects: 0
Study 18773723 — intervention group
Group type: COMPARATOR
Intervention: Luminance information (bright/dark) in motion integration; measured through eye-movement measures in 3-month-old infants.
Number of subjects: 0
Study 16195905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nystatin (3x10(6) U per day)
Number of subjects: 98
Study 16195905 — intervention group
Group type: COMPARATOR
Intervention: No nystatin (control group)
Number of subjects: 98
Study 12860576 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg/d, titrated to max 200 mg)
Number of subjects: 269
Study 12860576 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/d, titrated to max 10 mg)
Number of subjects: 269
Study 12860576 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 269
Study 12860576 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone and Amlodipine
Number of subjects: 269
Study 10583711 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid (DCA) 750 mg day‐1 for 3 weeks
Number of subjects: 13
Study 10583711 — intervention group
Group type: COMPARATOR
Intervention: Untreated gallstone patients
Number of subjects: 13
Study 9522686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared dentin surfaces were cleaned with Tubulicid Red Label and covered with Tubulitec Primer
Number of subjects: 12
Study 9522686 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Bond 2 Primer was applied to the prepared dentin surface
Number of subjects: 12
Study 9522686 — intervention group
Group type: COMPARATOR
Intervention: Control group: prepared surfaces were left unprotected after preparation
Number of subjects: 12
Study 2060527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (50 mg/day) plus Clindamycin (2.4 g/day)
Number of subjects: 281
Study 2060527 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine (50 mg/day) and Sulfadiazine (4.0 g/day)
Number of subjects: 281
Study 2060527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 281
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: thio-TEPA
Number of subjects: 0
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26
Number of subjects: 0
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: epodyl
Number of subjects: 0
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 0
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin
Number of subjects: 0
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: oral pyridoxine
Number of subjects: 0
Study 6416698 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin (Adriamycin)
Number of subjects: 0
Study 6416698 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 0
Study 31755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) on an accelerated dosing schedule (months 0, 2, and 6)
Number of subjects: 0
Study 31755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV) given concurrently with Japanese encephalitis (JE) vaccine
Number of subjects: 0
Study 31755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD‐TDV)
Number of subjects: 0
Study 31412035 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening intervention conducted in 28 villages
Number of subjects: 10963
Study 31412035 — intervention group
Group type: COMPARATOR
Intervention: Passive screening (historically used)
Number of subjects: 10963
Study 28576207 — intervention group
Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 32
Study 28576207 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6 tamponade
Number of subjects: 32
Study 26458331 — intervention group
Group type: EXPERIMENTAL
Intervention: Values inventory intervention
Number of subjects: 120
Study 26458331 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 120
Study 24438321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sTMS with fixed frequency at the subject's alpha frequency
Number of subjects: 52
Study 24438321 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sTMS with random stimulus frequency (8 Hz to 13 Hz)
Number of subjects: 52
Study 24438321 — intervention group
Group type: COMPARATOR
Intervention: Sham sTMS
Number of subjects: 52
Study 22284441 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal GFR estimates from creatinine‐based equations
Number of subjects: 846
Study 22284441 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR > 40 mL/min/1.73 m2 and urine protein‐creatinine ratio < 0.22 g/g
Number of subjects: 846
Study 18853090 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 90
Study 18853090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17270007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 29
Study 17270007 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 29
Study 15126520 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.0125 mg/kg.d, increased to 0.025 mg/kg.d as tolerated, or decreased to 0.00625 mg/kg.d for 12 months
Number of subjects: 166
Study 15126520 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 166
Study 11394590 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual SPM training (n = 16)
Number of subjects: 41
Study 11394590 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SPM training (n = 16)
Number of subjects: 41
Study 11394590 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 41
Study 9543436 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine (3TC)
Number of subjects: 1840
Study 9543436 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC plus loviride
Number of subjects: 1840
Study 9543436 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1840
Study 9543436 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 1840
Study 8036820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis A vaccine (0.1 ml each, three doses)
Number of subjects: 43
Study 8036820 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular hepatitis A vaccine (control group)
Number of subjects: 43
Study 2659740 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon‐alpha‐2C (rIFN‐alpha‐2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP)
Number of subjects: 33
Study 2659740 — intervention group
Group type: COMPARATOR
Intervention: VMCP chemotherapy alone
Number of subjects: 33
Study 31397611 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + Er,Cr:YSGG LAI
Number of subjects: 72
Study 31397611 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + Er,Cr:YSGG LAI
Number of subjects: 72
Study 31397611 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + PUI
Number of subjects: 72
Study 31397611 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + PUI
Number of subjects: 72
Study 31397611 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no treatment)
Number of subjects: 72
Study 31397611 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no bacteria)
Number of subjects: 72
Study 30273508 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to online resources, group and private forums, and videoconferencing with a therapist.
Number of subjects: 28
Study 30273508 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 28
Study 28578208 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 547
Study 28578208 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioural Therapy (ICBT)
Number of subjects: 547
Study 28578208 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 547
Study 26050967 — intervention group
Group type: EXPERIMENTAL
Intervention: V0162 (1600 μg)
Number of subjects: 20
Study 26050967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23456567 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 30986
Study 23456567 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin antiplatelets
Number of subjects: 30986
Study 23456567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator therapy (IV-tPA)
Number of subjects: 30986
Study 23456567 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent use
Number of subjects: 30986
Study 21480976 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin dressing
Number of subjects: 65
Study 21480976 — intervention group
Group type: COMPARATOR
Intervention: Control dressing
Number of subjects: 65
Study 18049795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban 0.4 microg/kg/min over 30 min plus 0.15 microg/kg/min over 24 h (Group A)
Number of subjects: 60
Study 18049795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg (Group B)
Number of subjects: 60
Study 18049795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg plus tirofiban (Group C)
Number of subjects: 60
Study 16736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message booklet with brief advice
Number of subjects: 575
Study 16736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice conditions (tailored or generic)
Number of subjects: 575
Study 16736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adult women (ages 19-22) who received brief advice
Number of subjects: 575
Study 16736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic message booklet with brief advice
Number of subjects: 575
Study 16736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic message booklet only
Number of subjects: 575
Study 16736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message booklet only
Number of subjects: 575
Study 12755777 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded FRIALIT-2(R) implants
Number of subjects: 7
Study 12755777 — intervention group
Group type: COMPARATOR
Intervention: Non-loaded implants
Number of subjects: 7
Study 10983904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (walking, jogging, cycling at 50-60% HRR for 30-45 minutes, progressing to 80-85% HRR for 45-60 minutes, 3-4 times per week for 9 months)
Number of subjects: 17
Study 10983904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 17
Study 8797143 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 10 mg and above
Number of subjects: 12
Study 8797143 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (various doses: 1, 5, 10, 25, 50, and 100 mg)
Number of subjects: 12
Study 8797143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1480537 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg trandolapril
Number of subjects: 8
Study 1480537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6737952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21
Study 6737952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29696916 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (at Fengchi, Ganshu, Shenshu, Quchi, Zusanli, Sanyinjiao, Taichong), once every two weeks for 3 months
Number of subjects: 125
Study 29696916 — intervention group
Group type: COMPARATOR
Intervention: Lotensin (10 mg, once a day)
Number of subjects: 125
Study 29696916 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 125
Study 29696916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 27170340 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (IL2Ra) 20 mg on Day 0 and Day 4
Number of subjects: 213
Study 27170340 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (rATG) 1.0 mg/kg/day from Day 0 to Day 4
Number of subjects: 213
Study 27170340 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (IL2Ra)
Number of subjects: 213
Study 27170340 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (rATG)
Number of subjects: 213
Study 26202784 — intervention group
Group type: EXPERIMENTAL
Intervention: Defatted cows' milk
Number of subjects: 13
Study 26202784 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially defatted cows' milk
Number of subjects: 13
Study 26202784 — intervention group
Group type: COMPARATOR
Intervention: Whole cows' milk
Number of subjects: 13
Study 24124716 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 5-40 mg injection in standard group (CVP < 8 mm Hg)
Number of subjects: 56
Study 24124716 — intervention group
Group type: COMPARATOR
Intervention: Control group (CVP not < 8 mm Hg)
Number of subjects: 56
Study 20807459 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pea flour (WPF)
Number of subjects: 23
Study 20807459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated pea flour (FPF)
Number of subjects: 23
Study 20807459 — intervention group
Group type: COMPARATOR
Intervention: White wheat flour (WF)
Number of subjects: 23
Study 18194332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash and oral gel containing lactoperoxidase, lactoferrin, and lysozyme
Number of subjects: 20
Study 18194332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16600923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products enriched with cis-9,trans-11 CLA (1.421 g/d)
Number of subjects: 32
Study 16600923 — intervention group
Group type: COMPARATOR
Intervention: Control dairy products (0.151 g/d CLA)
Number of subjects: 32
Study 14748110 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst TENS stimulation
Number of subjects: 18
Study 14748110 — intervention group
Group type: COMPARATOR
Intervention: No stimulus (control)
Number of subjects: 18
Study 10966004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 10966004 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridines (ticlopidine and clopidogrel)
Number of subjects: 0
Study 10966004 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 9348572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation therapy plus fluorouracil (5-FU)-based chemotherapy
Number of subjects: 0
Study 9348572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative bolus 5-FU/leucovorin combined-modality therapy
Number of subjects: 0
Study 9348572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur and uracil (UFT) with oral leucovorin plus pre- or postoperative radiation therapy
Number of subjects: 0
Study 8446442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (10‐16 mg)
Number of subjects: 16
Study 8446442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3743684 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.25 micrograms X kg‐1 X min‐1)
Number of subjects: 8
Study 3743684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 31669496 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based dietary education program for six months
Number of subjects: 92
Study 31669496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study 30266774 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 0
Study 30266774 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 0
Study 26542419 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity stationary cycling programme for 16 weeks
Number of subjects: 75
Study 26542419 — intervention group
Group type: COMPARATOR
Intervention: Control group with no exercise intervention
Number of subjects: 75
Study 26542419 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater compliance with exercise protocol
Number of subjects: 75
Study 24531785 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Number of subjects: 0
Study 24531785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23161117 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (70‐70.2 Gy in 35‐39 fractions)
Number of subjects: 19
Study 23161117 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (37.8‐55.8 Gy in 21‐31 fractions) followed by total laryngectomy
Number of subjects: 19
Study 23161117 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (with or without chemotherapy)
Number of subjects: 19
Study 23161117 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 19
Study 21397987 — intervention group
Group type: EXPERIMENTAL
Intervention: Double J ureteral catheter
Number of subjects: 194
Study 21397987 — intervention group
Group type: COMPARATOR
Intervention: Catheter-free
Number of subjects: 194
Study 19080093 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (10 ng/ml added into the prime solution and continuous pump infusion of 10 ng/kg/min via central vein until the end of operation)
Number of subjects: 58
Study 19080093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (20,000 U/kg divided into several doses added into the prime solution)
Number of subjects: 58
Study 19080093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Alprostadil and Ulinastatin (according to the above protocols)
Number of subjects: 58
Study 19080093 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 58
Study 16493178 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraindication label
Number of subjects: 466
Study 14570791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 8 mg + sufentanil 2.5 microg
Number of subjects: 90
Study 14570791 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 8 mg + sufentanil 2.5 microg
Number of subjects: 90
Study 14570791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 12 mg + sufentanil 2.5 microg
Number of subjects: 90
Study 11116071 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma lycopene levels (above median concentration)
Number of subjects: 520
Study 11116071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma lycopene levels (below median concentration)
Number of subjects: 520
Study 11116071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma lycopene levels
Number of subjects: 520
Study 8667097 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge clinic (once a week)
Number of subjects: 751
Study 8667097 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge practices
Number of subjects: 751
Study 1403459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gentamicin
Number of subjects: 68
Study 1403459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3801332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-harvest retted flax dust
Number of subjects: 11
Study 3801332 — intervention group
Group type: COMPARATOR
Intervention: Dew retted flax dust
Number of subjects: 11
Study 29275332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (240 mg/160 mg/160 mg; 80 mg/40 mg/40 mg; 160 mg/80 mg/80 mg and 560 mg/320 mg/320 mg)
Number of subjects: 53
Study 29275332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27746226 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV (live attenuated influenza vaccine)
Number of subjects: 1761
Study 27746226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1761
Study 27746226 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 1761
Study 25498067 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multidisciplinary rehabilitation program (GH method)
Number of subjects: 17
Study 25498067 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 17
Study 23210417 — intervention group
Group type: EXPERIMENTAL
Intervention: Test chewing gum containing zinc acetate 0.012% and magnolia bark extract 0.15%
Number of subjects: 123
Study 23210417 — intervention group
Group type: COMPARATOR
Intervention: Control chewing gum (sugar-free, without active agents)
Number of subjects: 123
Study 20110750 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 45
Study 18378844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia care management program (educational and supportive group for caregivers, 6 months duration)
Number of subjects: 88
Study 18378844 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study 18402944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 30